Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

Wall Street expects a year-over-year decline in earnings on lower revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] Zacks Style Scores - The Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow to find attractive investment opportunities [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify companies with sustainable growth potential [4] Momentum Score - The Momentum Style Score assists investors in capitalizing on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes to determine optimal entry points [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth forecasts, and promising momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8] Stock Selection Strategy - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential success, while stocks with lower ranks should also have strong Style Scores to mitigate risks [9][10] Company Spotlight: Gentex Corporation - Gentex Corporation, based in Zeeland, MI, specializes in automatic-dimming rear-view mirrors, fire protection products, and dimmable aircraft windows, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of A [11] - Gentex has a Momentum Style Score of A, with shares increasing by 2.1% over the past four weeks, and two analysts have raised their earnings estimates for fiscal 2026, increasing the Zacks Consensus Estimate by $0.04 to $1.97 per share, alongside an average earnings surprise of +3.8% [12]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence in investing [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score assesses a company's financial strength and future outlook based on projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stocks with strong value, growth forecasts, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary stock-rating model that uses earnings estimate revisions to assist in building a successful portfolio [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have A or B Scores to ensure potential upside [10] Company Spotlight: Prosperity Bancshares - Prosperity Bancshares, based in Houston, TX, operates through its bank subsidiary and is currently rated 3 (Hold) with a VGM Score of B [12] - The company has a Momentum Style Score of A, with shares increasing by 4% over the past four weeks, and an upward revision in earnings estimates for fiscal 2026 [13]

Company Overview - Plexus Corp., founded in 1979 and based in Neenah, WI, is a leading provider of electronic contract manufacturing services to original equipment manufacturers (OEMs) across various industries, including Healthcare/Life Sciences, Industrial, and Aerospace/Defense sectors [11]. Investment Ratings - Plexus Corp. currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating a solid overall performance [11]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of A, forecasting a year-over-year earnings growth of 2.4% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, two analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.12 to $7.61 per share [12]. - Plexus Corp. has demonstrated an average earnings surprise of +8.9%, suggesting a positive trend in earnings performance [12].

Company Overview - TD SYNNEX is a leading global IT distributor and solutions aggregator, providing a comprehensive range of technology distribution, logistics, and integration services [11] - The company was rebranded from SYNNEX Corporation to TD SYNNEX in September 2021 following its merger with Tech Data Corporation, which significantly expanded its global reach and vendor partnerships [11] Investment Ratings - TD SYNNEX currently holds a Zacks Rank of 3 (Hold) with a VGM Score of A, indicating a solid position in the market [12] - The company has a Growth Style Score of A, forecasting year-over-year earnings growth of 9.3% for the current fiscal year [12] Earnings Estimates - In the last 60 days, four analysts revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing by $0.06 to $14.42 per share [12] - TD SYNNEX boasts an average earnings surprise of +7.8%, suggesting a strong performance relative to expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TD SYNNEX is recommended as a potential top pick for growth investors [13]

Company Performance - Biofrontera Inc. (BFRI) has returned 55.7% year-to-date, significantly outperforming the average return of 4.3% for Medical companies [4] - The Zacks Consensus Estimate for BFRI's full-year earnings has increased by 700% over the past 90 days, indicating a strong improvement in analyst sentiment and earnings outlook [3] - Biofrontera Inc. is part of the Medical - Biomedical and Genetics industry, which has an average year-to-date return of 21%, further highlighting BFRI's superior performance [5] Industry Context - The Medical sector consists of 928 individual stocks and is currently ranked 10 in the Zacks Sector Rank [2] - The Medical - Biomedical and Genetics industry includes 449 companies and is ranked 90 in the Zacks Industry Rank [5] - Brookdale Senior Living (BKD), another Medical stock, has returned 38.1% year-to-date and is part of the Medical - Nursing Homes industry, which has a year-to-date return of +7.2% [4][6]

Core Viewpoint - Veracyte (VCYT) has experienced a significant downtrend, with a 20% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - VCYT's current RSI reading is 28.44, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - Analysts covering VCYT have shown strong consensus in raising earnings estimates, with a 0.8% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - VCYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Viewpoint - S&P Global (SPGI) has experienced a significant decline of 13.4% over the past four weeks, but it is now in oversold territory, indicating a potential for a trend reversal as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - SPGI's current RSI reading is 23.41, suggesting that the heavy selling pressure may be exhausting itself and a trend reversal could occur soon [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that SPGI's earnings estimates for the current year have increased by 0.8% over the last 30 days, which usually correlates with price appreciation [7]. - SPGI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].

Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to report its fourth-quarter and full-year 2025 results on February 10, with consensus estimates for sales at $7.57 billion and earnings per share (EPS) at $1.83 [1][5] Financial Estimates - The earnings estimate for 2025 has decreased to $8.13 from $8.18 per share over the past 60 days, while the estimate for 2026 has increased to $8.60 from $8.56 [1] - The current earnings estimates for Q1 and Q2 are $1.83 and $1.90, respectively, with a trend showing a decrease of 3.17% for Q1 and an increase of 2.70% for Q2 over the past 60 days [2] Earnings Performance - GILD has a strong earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 7.80%, including a 14.88% beat in the last reported quarter [2][3] Product Performance - Gilead's HIV franchise, particularly Biktarvy and Descovy, remains the primary growth driver, with Biktarvy accounting for over 52% of the U.S. treatment market [5][8] - The estimated sales for Biktarvy and Descovy are $3.8 billion and $703 million, respectively, with Yeztugo contributing $39 million in the third quarter [9][10] - The liver disease portfolio has seen increased sales, particularly for Livdelzi, while cell therapy sales are expected to decline due to competitive pressures [12][13] Market Position and Valuation - GILD's shares have increased by 49.2% over the past year, outperforming the industry growth of 31% [15] - The current price/earnings ratio for GILD is 16.85x forward earnings, higher than its historical mean of 11.17x but lower than the large-cap pharma industry average of 18.13x [18] Strategic Initiatives - Gilead is focusing on innovation within its HIV portfolio and has received positive data from phase III studies for new treatments [19][20] - The company is also pursuing strategic collaborations, including partnerships with Merck to enhance its product offerings [25]